[go: up one dir, main page]

MX2023000230A - Uso de inhibidor de caspasa para aliviar o tratar osteoartritis. - Google Patents

Uso de inhibidor de caspasa para aliviar o tratar osteoartritis.

Info

Publication number
MX2023000230A
MX2023000230A MX2023000230A MX2023000230A MX2023000230A MX 2023000230 A MX2023000230 A MX 2023000230A MX 2023000230 A MX2023000230 A MX 2023000230A MX 2023000230 A MX2023000230 A MX 2023000230A MX 2023000230 A MX2023000230 A MX 2023000230A
Authority
MX
Mexico
Prior art keywords
relieve
caspase inhibitor
treat osteoarthritis
osteoarthritis
treat
Prior art date
Application number
MX2023000230A
Other languages
English (en)
Inventor
Jung Gyu Park
Min Kyoung Lee
Sung Won Kim
Myung Won Jin
Hyun Seo Park
Jae Uk Baek
Sei Hyun Choi
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2023000230A publication Critical patent/MX2023000230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se relaciona a un uso de un inhibidor de caspasa para aliviar o tratar osteoartritis.
MX2023000230A 2020-08-05 2021-08-04 Uso de inhibidor de caspasa para aliviar o tratar osteoartritis. MX2023000230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200098151 2020-08-05
PCT/KR2021/010209 WO2022030987A1 (ko) 2020-08-05 2021-08-04 캐스파제 저해제의 골관절염 완화 또는 치료에서의 용도

Publications (1)

Publication Number Publication Date
MX2023000230A true MX2023000230A (es) 2023-02-09

Family

ID=80117432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000230A MX2023000230A (es) 2020-08-05 2021-08-04 Uso de inhibidor de caspasa para aliviar o tratar osteoartritis.

Country Status (12)

Country Link
US (1) US20230310412A1 (es)
EP (1) EP4173622A4 (es)
JP (1) JP7566405B2 (es)
KR (1) KR20220017851A (es)
CN (1) CN116113413A (es)
AU (1) AU2021321068B2 (es)
BR (1) BR112022026725A2 (es)
CA (1) CA3185212A1 (es)
MX (1) MX2023000230A (es)
TW (1) TW202220655A (es)
WO (1) WO2022030987A1 (es)
ZA (1) ZA202302270B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458347A4 (en) * 2022-01-24 2025-04-30 LG Chem, Ltd. ISOXAZOLINE DERIVATIVE-CONTAINING INJECTABLE FORMULATION
CN118574603A (zh) * 2022-02-23 2024-08-30 株式会社Lg化学 包含异𫫇唑啉衍生物的注射制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
US7411000B2 (en) * 2001-03-15 2008-08-12 The Scripps Research Institute Process of inhibiting cell death in injured cartilage
KR100774999B1 (ko) 2005-02-26 2007-11-09 주식회사 엘지생명과학 이소옥사졸린 유도체 및 그의 제조 방법
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
CN107007587A (zh) * 2013-03-15 2017-08-04 加州生物医学研究所 用于诱导软骨形成的化合物和方法
WO2017110094A1 (ja) * 2015-12-24 2017-06-29 学校法人同志社 カスパーゼ阻害剤を含む、ＴＧＦ－βに起因する障害を治療または予防するための医薬およびその応用
US20190022043A1 (en) * 2015-12-31 2019-01-24 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
IL268751B (en) * 2017-03-13 2022-08-01 Genfit Pharmaceutical preparations for combined treatment
KR102699958B1 (ko) * 2017-04-18 2024-08-29 장피트 엘라피브라노르와 같은 ppar 작용제 및 아세틸-coa 카르복실라아제 (acc) 저해제를 포함하는 조합

Also Published As

Publication number Publication date
CN116113413A (zh) 2023-05-12
AU2021321068B2 (en) 2025-01-02
US20230310412A1 (en) 2023-10-05
EP4173622A4 (en) 2023-07-05
CA3185212A1 (en) 2022-02-10
ZA202302270B (en) 2024-05-30
EP4173622A1 (en) 2023-05-03
BR112022026725A2 (pt) 2023-02-14
JP2023537012A (ja) 2023-08-30
TW202220655A (zh) 2022-06-01
WO2022030987A1 (ko) 2022-02-10
AU2021321068A1 (en) 2023-02-02
KR20220017851A (ko) 2022-02-14
JP7566405B2 (ja) 2024-10-15

Similar Documents

Publication Publication Date Title
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
BR112022015110A2 (pt) Compostos e usos dos mesmos
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
BR112022015109A2 (pt) Compostos e usos dos mesmos
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112022014949A2 (pt) Compostos e usos dos mesmos
BR112024001180A2 (pt) Composições e métodos para tratamento do melanoma
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
MX2023000230A (es) Uso de inhibidor de caspasa para aliviar o tratar osteoartritis.
MX2022007457A (es) Metodos para tratar el coronavirus.
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
CL2019000228A1 (es) Tratamiento conjunto contra tipos de cáncer hematológico.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112023015590A2 (pt) Antagonistas de gpr84 e usos dos mesmos
EA202191358A1 (ru) Новые соединения и их применение в лечении
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
BR112017025263A2 (pt) método para o tratamento de doença neurológica
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
MX2022000783A (es) Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales.
BR112022003768A2 (pt) Compostos inibidores de perk
BR112022001062A2 (pt) Inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt)
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака